Lobular cancer
Drug research and approvals for lobular cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 103 studies of lobular cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 103
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisNCT07914764 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Aug 1, 2026
- FES PET/MRI for Occult Disease in Lobular Breast CancerNCT07910474 · Phase 4 · University of Wisconsin, Madison · starts Nov 1, 2026
- Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryNCT07762885 · Phase 3 · Fudan University · starts Jul 1, 2026
- Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryNCT07762924 · Phase 2 · Fudan University · starts Sep 1, 2026
- Personalized Prone Immobilization for Accelerated Partial Breast RadiotherapyNCT07711847 · Not applicable · HeroSupport SA · starts Jul 2, 2026
- Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)NCT07709052 · Not reported · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · starts Oct 21, 2026
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07702292 · Phase 2 · Blue Earth Diagnostics · starts Jun 30, 2026
- Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic CancerNCT07659639 · Not applicable · Fondazione Policlinico Universitario Campus Bio-Medico · starts Sep 1, 2025
- Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsNCT07630961 · Phase 1 · Novartis Pharmaceuticals · starts Jun 23, 2026
Phase 3 2
- AnastrozoleCytochrome P450 19A1 inhibitor
- FulvestrantEstrogen receptor alpha antagonist
Phase 2 6
- Doconexent
- GoserelinGonadotropin-releasing hormone receptor agonist
- LetrozoleCytochrome P450 19A1 inhibitor
- EntrectinibNeurotrophic tyrosine kinase receptor inhibitor
- Icosapent
- FluoroestradiolDiagnostic agent
Phase 1 or earlier 2
- GozetotideDiagnostic agent
- FluciclovineDiagnostic agent
How its trials ended
69 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 11 whose ending is known, 45% met their primary endpoint, 9% missed it and 45% stopped early.
- Ongoing3348%
- Completed, result not reported1928%
- Status unknown69%
- Met its primary endpoint57%
- Stopped: other or unclear46%
- Missed its primary endpoint11%
- Stopped: enrollment or feasibility11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA